Arabic Arabic English English French French German German
dark

No benefit seen from adjuvant celecoxib in ERBB2-negative breast cancer

(HealthDay)—For patients with ERBB2-negative breast cancer, two years of treatment with celecoxib as adjuvant to conventional therapy yields no disease-free survival (DFS) benefits compared with placebo, according to a study published online July 15 in JAMA Oncology. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Doctors for COVID Ethics: Halt Use of Pfizer COVID Vaccines in Adolescents ‘Immediately’

Next Post

Study identifies monoclonal antibodies that may neutralize many norovirus variants

Related Posts
Total
0
Share